Kornimate/medical-research-clean huggingface dataset:
the effect of rapid transcranial magnetic stimulation (rtms) on aggression in forensic patients

Conditions: Aggression

Summary: forensic patients will undergo 30 rtms treatments, once per day each business day using a 1hz frequency at the right dorso-lateral pre frontal cortex, located using modified beam f3. patients will be assessed before and after the study with a battery of assessments and using 2 computer tasks: a ball passing task, and the point subtraction aggression paradigm (psap). the investigators will also monitor and record aggressive incidents that take place on the unit.


Eligibility criteria:
inclusion criteria: 1. are voluntary and competent to consent to treatment 2. are a current forensics inpatient at st. joseph's west 5th campus 3. demonstrate aggressive behavior as confirmed by a psychologist or psychiatrist including verbal and physical aggression 4. are between the ages of 18 and 65 5. have had no changes in dose or initiation of any psychotropic medication in the 4 weeks prior to motor threshold 6. are willing and able to adhere to the treatment schedule 7. pass the tms adult safety-screening (tass) questionnaire exclusion criteria: 1. withdraw consent to participate in the study 2. fail the tass safety screening questionnaire 3. have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump, or a significant history of seizures 4. have active suicidal intent 5. are pregnant as confirmed by pregnancy test completed as part of pre-study screening 6. have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any significant history of seizure except those therapeutically induced by electroconvulsive therapy (ect), cerebral aneurysm, parkinson's disease, huntington's chorea, multiple sclerosis 7. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed 8. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent) due to seizure risk or any dose of an anticonvulsant due to the potential to limit rtms efficacy 9. non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).

Keywords: rtms repetitive transcranial magnetic stimulation brain stimulation
effect of levcromakalim in individuals with migraine pretreated with erenumab

Conditions: Migraine Without Aura

Summary: an outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (cgrp) receptor monoclonal antibody).


Eligibility criteria:
inclusion criteria: * participant has provided informed consent prior to initiation of any study-specific activities/procedures. * age ≥18 years upon entry into screening. * history of migraine without aura for ≥12 months with a frequency of 1-5 migraine attacks per month before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018), based on medical records and/or patient self-report. exclusion criteria: * history of any primary headache disorder other than migraine without aura, or tension-type headache with a frequency of ≥5 headache days per month before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018), based on medical records and/or patient self-report. * history of any secondary headache disorder before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018) based on medical records and/or patient self-report. * intake of prophylactic migraine medication within ≤30 days or 5 plasma half-lives (whichever is longer) prior to screening. * prior intake of therapies targeting the cgrp signaling pathway, including anti-cgrp ligand monoclonal antibodies, anti-cgrp receptor monoclonal antibodies, and small molecule cgrp receptor antagonists. * the participant is at risk of self-harm or harm to others as evidenced by past suicidal behavior. * history or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator will pose a risk to participant safety or interfere with the study evaluation, procedures or completion. * female participants of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test. * female participants who are pregnant or breastfeeding or plan to become pregnant or breastfeed during participation in the study. * evidence of current pregnancy or breastfeeding per participant self-report or medical records. * participants likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participants' and investigator's knowledge.
endostar first-line treatment of advanced non-small cell lung squamous carcinoma

Conditions: Advanced Lung Squamous Carcinoma

Summary: explore the efficacy and safety of the treatment of endostar continuous intravenous injection pump combined dp scheme for first-line advanced lung squamous carcinoma and maintenance treatment., and explore the predicted biomarkers.


Eligibility criteria:
inclusion criteria: 1. cytological and histological confirmation（do not accept single sputum cytology in the diagnosis of patients） in patients diagnosed of lung squamous carcinoma; 2. according to a new iaslc2009 lung cancer tnm stages judged stage iiib or iv non-small cell lung cancer. 3. must have at least one evaluated lesion,according to the rrecist version 1.1 standard (the longest diameter on spiral ct at least 10 mm,the longest diameter on plain ct at least 20 mm); 4. male or female, age between 18 and 75 years old ; 5. ecog ps 0\~1； 6. expected survival period ≥ 3 months or more 7. enough blood function: absolute neutrophil count (anc)≥2 x 109 / l and the platelet count≥ 100 x 109 / l and hemoglobin ≥9 g/dl; 8. enough liver function: total bilirubin acuities≤the upper limit of normal (uln); ast and alt acuities ≤2.5 times of the upper limit of normal (uln); alkaline phosphatase ≤5 times of the upper limit of normal(uln); 9. enough renal function：serum creatinine ≤the limit of normal(uln) or calculated creatinine clearance≥60 ml/min. 10. the electrocardiogram (ecg) basicaly normal,the body had no to heal wounds 11. no previous anti-tumor drug therapy, or only received for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the study start. 12. patients had surgery before,but have more than 4 weeks before the study star, and the patient has recovered; 13. women with cmpleted uterus before intact in the group within 28 days must have a negative pregnancy test results (unles amenorrhea for 24 months). if the pregnancy test from the first time for more than 7 days,the patients need for urine pregnancy test(within 7 days before the first delivery). 14. prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions; 15. sign the informed consent. exclusion criteria: 1. pregnancy, nursing mothers, or female patients with fertility but no contraception. 2. existing serious acute infection, and can not be controlled; or with fester sex and chronic infection,or wound in delay; 3. original serious heart disease, including: congestive heart failure, uncontroled high risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension; 4. with uncontroled nerve, mental illness or mental disorders, compliance is poor, can't cooperate and response to treatment; uncontroled primary brain tumors or cns metastases illness, with obvious symptoms in cranial hypertension or nerve spirit; 5. with a bleeding tendency 6. researchers believe that patients should not participate in this test.

Keywords: endostar,advanced lung squamous carcinoma
the role of low level laser therapy in acceleration of teeth alignment in lingual orthodontic patients

Conditions: Malocclusion, Angle Class I; Crowding

Summary: we will treat patients with class i malocclusion who have moderate crowding (4-6 mm) according to little's irregularity index and asses the efficacy of low level laser therapy in accelerating orthodontic tooth movement . there is two groups : 1. treated with low level laser therapy (lllt) 2. treated traditionally without any irradiation patients will be randomly allocated in any group and all data will be collected through photographs when leveling and alignment completed. also pain levels will be assessed using numeric rating scale to compare between the two groups and if laser really can relief pain or not .

the time of orthodontic treatment is considered to be one of the most concerns for patients. the study will investigate the effect of low level laser therapy on the speed of orthodontic tooth movement during the correction of moderately crowded anterior upper teeth using lingual orthodontic appliance. the study will be accomplished with two arms, the first is lllt arm and the other is the control arm without any active intervention. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 j per each tooth. within the limits of our knowledge, this is the first study in the world that will study acceleration of orthodontic tooth movement with lingual orthodontic .

Eligibility criteria:
inclusion criteria: * class i malocclusion with mild to moderate crowding * old between 17-27 years * good oral hygiene * patients should be fit and well * 4-6 mm crowding in upper incisors according to little's index * enough clinical crowns length exclusion criteria: * patients who had an old orthodontic treatment * people who have any drug or disease affect orthodontic movement * any contraindication for orthodontic treatment
a pilot study of diffusion weighted mri to assess esophageal tumor resonse to neoadjuvant chemoradiation

Conditions: Esophageal Cancer

Summary: the purpose of this research study will be to determine the sensitivity and specificity of dwmri metrics to assess tumor response following neoadjuvant chemoradiation in esophageal cancer. this pilot study will generate the preliminary data needed for the design of a statistically-justified trial that would investigate dwmri as an integral biomarker to stratify patients for escalated therapy to improve outcomes. we hope to develop dwmri as a predictive clinical tool for a personalized treatment model that can identify patients who may be candidates for organ-preservation or treatment intensification to improve outcomes in esophageal cancer.


Eligibility criteria:
inclusion criteria: * patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina * patients with ajcc 7th edition clinical stage iib-iiic * patients will be treated with neoadjuvant chemoradiotherapy for this condition * patients must be \> 18 years of age * patients must be able to provide informed consent * patients must be surgical candidates * patients must be able to tolerate mr imaging required by protocol exclusion criteria: * patients with primary tumors located above the carina * prior abdominal radiation therapy with fields overlapping the current fields * severe claustrophobia not relieved by oral anxiolytics per institutional standard practice * presence of mri-incompatible metallic objects or implanted medical devices in the body (including but not limited to: non-mri compatible metal objects, cardiac pacemaker, aneurysm clips, artificial heart valves with steel parts, metal fragments in the eye or central nervous system) * weight greater than that allowable by the mri table
the pancreatic enzymes after gastrectomy trial

Conditions: Gastrectomy

Summary: this trial evaluates the effects (e.g. on quality of life, weight) of nortase® compared to standard care of patients who have undergone gastrectomy.


Eligibility criteria:
inclusion criteria: 1. gastrectomy (total and partial) 2. age 18 or older 3. written informed consent exclusion criteria: 1. indication for pancreas enzyme therapy 2. gastrectomy with palliative intention 3. uicc (union for international cancer control) stage iv gastric malignancy 4. malnutrition of other aetiology 5. life expectancy \< 12 months 6. known lactose intolerance 7. known hereditary galactose intolerance 8. patients on alpha-glucosidase inhibitors (agis) 9. acute pancreatitis 10. acute episode of chronic pancreatitis 11. known hypersensitivity to moulds (mould allergy) or any other ingredient of nortase® 12. participation in competing interventional trials may be allowed under circumstances 13. patients under legal supervision or guardianship 14. patients who are dependent on the investigator or the medical staff of the trial team or the coordinating investigator or the sponsor 15. fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial 16. pregnant or nursing women 17. suspected lack of compliance 18. patients who were already enrolled in the trial

Keywords: enzyme supplementation lipase elastase gastrointestinal quality of life
clinical intuition for predicting evolution in sepsis in the emergency department - cipres-ed study

Conditions: Sepsis

Summary: sepsis is a syndrome involving infection and an abnormal systemic inflammatory response in the infected organism, resulting in organ dysfunction and possibly death. it is a major cause of hospital mortality. a large proportion of sepsis diagnoses are made in emergency departments. early diagnosis and appropriate treatment have been shown to reduce mortality from this disease. in a context of limited resources, it is therefore important to be able to quickly stratify patients presenting to the emergency department with a suspected infection into those who require rapid and intensive management because they are at risk of developing sepsis and septic shock and those who can be managed conventionally the objective of this study is to compare the clinical intuition of emergency room physicians and nurses with the qsofa score to predict the clinical course of patients presenting to the emergency room with potential sepsis.


Eligibility criteria:
inclusion criteria: * patients presenting to one of the participating emergency departments with suspected infection, defined as the presence of at least one of these parameters: temperature ≥ 38°c ou \< 36°c measured in the emergency room chills (in the emergency room or on recent history) * no objection to participation in the study exclusion criteria: * minor patient (\<18 years) * patient under guardianship or other protective measure * patient unable to understand research information * patient refusing the use of their data for research purposes

Keywords: sepsis clinical intuition emergency department
mobilizing evidence into action to improve outcomes of vulnerable seniors

Conditions: Hip Fractures; Femoral Fractures

Summary: this is a parallel randomized controlled trial comparing two different delivery modes of post hip fracture management-a specialized fracture follow-up clinic versus usual care alone. the fracture follow-up clinic will focus on bone health and fall risk factors. the investigators will evaluate the effect of the clinic and exercise program on mobility and falls. the investigators primary hypothesis is that within the first year following a hip fracture, older adults who are assessed in the b4 clinic and prescribed an exercise program will have significantly improved short physical performance battery (sppb) scores compared with participants who receive usual care alone.


Eligibility criteria:
inclusion criteria: * 65 years + * community-dwelling * residents of metro vancouver * recent history (within 12 months) of femoral fracture exclusion criteria: * unable to ambulate 10 meters prior to the femoral fracture were(with/without a walking aid) * discharged to a residential care facility * and/or diagnosed with any type of dementia (alzheimer's, vascular etc.)

Keywords: exercise hip fractures rehabilitation aged aged 80 and over
consecutive dual-session tdcs in chronic subjective severe to catastrophic tinnitus with normal hearing

Conditions: Tinnitus, Subjective

Summary: we aimed to analyze the effect of continuous dual session tdcs in patients with severe chronic subjective tinnitus without any evidence of hearing loss in terms of relief of tinnitus perception, distress, and loudness. also, we investigated the difference in the maintenance duration of the tinnitus suppression effect of consecutive dual session tdcs compared to other groups followed up for 2 months.

the participants were randomly allocated with three different arms (control, single-session, and dual session) using block to balance the size of each group. pure tone audiometry, speech audiometry, tinnitogram (pitch matching, loudness, minimal masking level and residual inhibition), auditory evoked potential, thi, visual analogue scale (vas) of loudness, awareness and annoyance, and bdi were evaluated as a baseline tests. participants who assigned to the control group underwent dual sham stimulation per day, twice a week for 1 month. patients were received sham and true stimulation once alternately in the single session group and two true stimulation per day in the dual session group for the same period as the control group. all subjects who enrolled this study were given a conventional treatment such as tinnitus retraining therapy, sound therapy using sound generator, and medications like clonazepam, selective serotonin reuptake inhibitors for patients who wanted to take for relief of symptoms.

Eligibility criteria:
inclusion criteria: * individuals who have experienced subjective tinnitus for over 3 months. * individuals with normal hearing, defined as an average pure tone threshold of less than 25 db between 0.5-4 khz, and the presence of the v wave at 30 dbnhl with a difference in v wave latency of less than 0.2 ms in both ears during the abr test. * individuals with severe tinnitus, as indicated by a tinnitus handicap inventory (thi) score of 58 or higher, and who have been assessed for symptoms of anxiety and depressive mood using the beck depression inventory (bdi) questionnaire. exclusion criteria: * those requiring treatment for neurological disorders such as epilepsy, migraine, or intracranial masses. * pregnant individuals on the day of providing consent and those with metal-based electric implantable prosthetics. * individuals with objective or somatic tinnitus, auditory hallucinations, unwillingness to provide written consent, or unwillingness to continue the trial, and those who have participated in previous trials involving tdcs for tinnitus.

Keywords: transcranial direct current stimulation tinnitus
tape versus semirigid versus lace-up ankle support in the treatment of acute lateral ankle ligament injury.

Conditions: Grade II and III Acute Lateral Ankle Ligament Injuries

Summary: the objective of this study is to compare tape versus semi rigid support versus lace up brace treatment for acute lateral ankle ligament injuries with regard to clinical outcome and cost effectiveness. there is a difference of 10 in functional outcome (karlsson score) between non-elastic adhesive taping and semi-rigid and lace-up ankle support, in favour of the last, for the treatment of acute lateral ankle ligament injury at 6 months follow-up.

this study is designed as a single blind prospective randomized controlled trial to evaluate the difference in functional outcome after treatment with tape versus semi-rigid versus lace-up ankle support (brace) for grade ii and iii acute lateral ankle ligament injuries. the patients will be randomly allocated into one of the three groups. randomization will be performed by computer. blinding of patients is not possible, but the observer will be blinded at eight weeks and six months.

Eligibility criteria:
inclusion criteria: * patients \> 18 years * grade ii or iii ankle sprains * presentation \< 72 hours after the acute injury exclusion criteria: * patients with a history of chronic instability * who had a fracture on x-ray investigation * other injuries or disabilities on the same limb * alcoholism, serious psychiatric and neurological illness * patients with bilaterally sprained ankles * patients with previous surgery on the lateral ankle ligaments * skin diseases where taping is not practicable * patients who are unable to give informed consent * patients who are unable to fill out questionnaires * neuromuscular disorders of the lower extremities * active rheumatoid arthritis * gait disturbances

Keywords: ankle ligament injuries non-surgical treatment tape brace orthotic device bandage cost-effectiveness randomized trial
comparison of two liver dialysis systems : mars versus spad in severe liver failure

Conditions: Liver Failure, Acute; Chronic Hepatic Failure

Summary: a critical issue of the clinical syndrome in liver failure is the accumulation of toxins not cleared by the failing liver. based on this hypothesis, albumin dialysis is used to remove those substances. albumin dialysis with recirculation (mars) is the most used system but required specific system and expert environment. alternative system without recirculation (spad) is less expensive and can be realised in critical care services trained to extrarenal epuration. the primary objective of this study is to compare biological and clinical efficacy, pulsatility index of middle cerebral artery modification and tolerance of both systems. this is a prospective, open, cross-over comparative study of two albumin dialysis system. each patient will receive the two systems in an randomly assessed order. patients are divided up according to bilirubin plasmatic level. (250µmol/l to 400 µmol/l and \>400µmol/l).


Eligibility criteria:
inclusion criteria: * severe hepatic failure on acute liver failure or acute on chronic liver failure * hyperbilirubinemia (total plasmatic bilirubin level above 250µmol/l) * hepatic encephalopathy or pruritus or hepatorenal syndrome. * waiting for liver function recovery or liver transplantation * signed written informed consent by patient or patient's legally appointed representative or reliable person * affiliation to social security exclusion criteria: * contraindication to extra-renal epuration * hypersensibility to albumin or excipients * patients for whom 2 albumin dialysis treatment cannot be considered